Our corporate offices are located at:

675 Arapeen Drive
Suite 202
Salt Lake City, Utah 84108

Our telephone number is (801) 994-7383.

Lipocine Inc. is incorporated in the State of Delaware.

Lipocine became a public company through a reverse merger in July 2013. Immediately following the reverse merger, Lipocine raised $38 million in a private placement to institutional investors at $6.00 per share.

Our fiscal year end is December 31st.

Lipocine's stock is listed on the NASDAQ capital market under the symbol LPCN.

Lipocine has never declared or paid any cash dividends to its shareholders. We do not anticipate paying cash dividends to our shareholders in the foreseeable future as we intend to retain future earnings to finance the growth and development of our business.

Lipocine’s transfer agent is:

Equiniti Trust Company, LLC
1110 Centre Point Curve, Suite #101
Mendota Heights, MN 55120
(718) 921-8124

If your shares are held in your name, please contact Equiniti’s Shareholder Services Call Center at (800) 937-5449 (in the US) or (718) 921-8124 (international) during the hours of 8:00 am – 8:00 pm ET, Monday through Friday for assistance. You may also email helpast@equiniti.com or access your account at https://equiniti.com/us/ast-access. If your shares are held in street name, please contact your broker directly for assistance.

Lipocine does not have a direct stock purchase plan.

You may obtain more information about Lipocine by visiting our website at www.lipocine.com or by contacting us at our corporate address or phone number.

Our independent auditor is:

Tanner LLC
36 S State Street #600
City Creek Center
Salt Lake City, Utah 84111
(801) 532-7444

Our legal counsel is:

Dorsey & Whitney LLP
111 South Main Street
Suite 2100
Salt Lake City, Utah 84101
(801) 933-7360